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ABSTRACT
The retinoic acid receptor-related orphan receptor
(ROR) alpha has been demonstrated to regulate lipid
metabolism. We were interested in the RORa1
dependent physiological functions in skeletal
muscle. This major mass organ accounts for
 40% of the total body mass and significant levels
of lipid catabolism, glucose disposal and energy
expenditure. We utilized the strategy of tar-
geted muscle-specific expression of a truncated
(dominant negative) RORa1"DE in transgenic mice
to investigate RORa1 signaling in this tissue.
Expression profiling and pathway analysis indicated
that RORa influenced genes involved in: (i) lipid and
carbohydrate metabolism, cardiovascular and
metabolic disease; (ii) LXR nuclear receptor signal-
ing and (iii) Akt and AMPK signaling. This analysis
was validated by quantitative PCR analysis using
TaqMan low-density arrays, coupled to statistical
analysis (with Empirical Bayes and Benjamini–
Hochberg). Moreover, westerns and metabolic
profiling were utilized to validate the genes,
proteins and pathways (lipogenic, Akt, AMPK and
fatty acid oxidation) involved in the regulation of me-
tabolism by RORa1. The identified genes and
pathways were in concordance with the demon-
stration of hyperglycemia, glucose intolerance,
attenuated insulin-stimulated phosphorylation of
Akt and impaired glucose uptake in the transgenic
heterozygous Tg-RORa1"DE animals. In conclu-
sion, we propose that RORa1 is involved in
regulating the Akt2-AMPK signaling pathways in
the context of lipid homeostasis in skeletal muscle.
INTRODUCTION
Retinoic acid receptor related orphan receptor alpha
(RORa) is an orphan member of the nuclear receptor
superfamily of transcription factors. Several in vitro and
in vivo studies on RORa action and function (1–5) have
suggested the involvement of this orphan nuclear receptor
in lipid homeostasis (6) and hepatic phase I/II metabolism
(7). RORa can be detected in many metabolic tissues
including liver, kidney, adipose tissue and is highly
expressed in skeletal muscle. In mice, RORa deﬁciency
leads to profound metabolic disturbances. The homozy-
gous staggerer (sg/sg) mice have a global RORa defect
that results in decreased and dysfunctional expression
of both mouse isoforms of RORa (1 and 4). These
mice display hypoalphalipoproteinemia, dyslipidemia
(decreased serum triglycerides and HDL-cholesterol) (5),
susceptibility to atherosclerosis (2) and reduced adiposity
and resistance to diet-induced obesity (8). The complex
phenotype of the staggerer mice has been demonstrated
to involve underlying changes in the expression of genes
involved in fatty acid homeostasis, i.e. Apo-lipoprotein A1
(ApoA1) (5), Apo-lipoprotein C3 (ApoCIII) (1), sterol
regulatory element-binding protein 1c (SREBP-1c),
ATP-binding cassette transporter-binding proteins A1
and G1 (ABCA1 and G1), peroxisome proliferator-
activated receptor gamma co-activator alpha/beta
(PGC-1a/b), lipin1 and beta2-adrenergic receptor (8).
In the context of whole body metabolism, skeletal
muscle has a vital contribution to the maintenance of
energy balance. It is a major mass peripheral tissue with
high energy demands. Consequently, multiple metabolic
pathways converge in this tissue involving the utilization
of both lipid and carbohydrate substrates. Skeletal muscle
is considered a major site of glucose disposal and perturb-
ation of insulin-mediated glucose uptake in this tissue is
an important factor in the development of type 2 diabetes.
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skeletal muscle has been associated with increased intra-
muscular triglyceride accumulation, which can attenuate
several insulin signaling pathways (9). As type 2 diabetes
and associated complications are health issues that have
global signiﬁcance, it is therefore of considerable interest
to investigate the regulatory machinery responsible for
maintaining tight metabolic control in this tissue.
Previously, our analysis of skeletal muscle from stagger-
er mice (8) identiﬁed diﬀerential expression of a number of
genes involved in fatty acid homeostasis. In this study, we
aimed to investigate the role of RORa in skeletal
muscle, without the complex interactions that result
from the global defect. Therefore, we generated a trans-
genic mouse that overexpressed truncated human
RORa1DE (lacking the ligand-binding domain) in
skeletal muscle to investigate the contribution of this
energy demanding tissue to the RORa phenotype. We
used a three-pronged genomic approach, utilizing
llumina expression proﬁling, Ingenuity function and
pathway analysis, and validation by rigorous quantitative
PCR (qPCR) analysis on the TaqMan low density array
(TLDA) platform. This demonstrated that RORa has an
important role in the regulation of carbohydrate and lipid
metabolism in skeletal muscle. In particular, this animal
model demonstrated that RORa1 also plays a critical role
in skeletal muscle insulin signaling and glucose tolerance,
via modulation of Akt2 and adenosine monophosphate
kinase (AMPK) expression and activity. This correlated
with increased expression of phospho ACC and genes
involved in the regulation of fatty acid oxidation. In con-
clusion, we propose that in skeletal muscle RORa1i sa n
important metabolic regulator, contributing to both
glucose and fatty acid homeostasis.
MATERIALS AND METHODS
Production of transgenic-mouse
The transgenic vector construct encodes a truncated
version of human RORa1 (RORa1DE). Amino acids
1–235 are present but the entire E region and part of the
hinge/D region have been removed as previously described
(3). To confer muscle speciﬁcity, the vector was placed
under the control of the full-length human skeletal
alpha-actin (HSA) promoter as described previously
(10–12). Zygotes were generated by pronuclear microinjec-
tion of the transgene into oocytes from hybrid female
donors (C57BL/6J X CBA) as described (13). Screening
of founder mice and their oﬀspring for stable germ line
transmission was performed by real time PCR. The se-
quences of the speciﬁc mouse RORa and human RORa
primers were as follows—hRORa: CAATGCCACCTA
CTCCTGTCC and CTACGGCAAGGCATTTCTGT
AAT, mRORa: CAATGCCACCTACTCCTGTCC and
GCCAGGCATTTCTGCAGC. Transgene copy number
was determined using real time PCR as described (14).
Two founders were selected for analysis, each of which
carried two copies of the transgene. Both lines were then
backcrossed with C57Bl/6J mice for a minimum of ﬁve
generations. Experiments were performed on transgenic
mice from the ﬁfth generation onward, relative to wt
littermates; therefore the genetic background of the
animals in this study is >98.6% C57Bl/6J. The initial
characterization was performed on both transgenic lines.
No diﬀerences were observed in either phenotype or meta-
bolic gene expression between the two lines, therefore we
continued investigation on one line only.
Animal procedures
The mice were housed in the QBP vivarium (University of
Queensland, St. Lucia, Queensland, Australia) with 12h
light–dark cycle and fed a standard diet containing 4.6%
total fat (from Specialty Feeds, Glen Forrest, Western
Australia). For the diet-induced obesity experiments,
mice were transferred to a high-fat diet containing
34.9% fat (D12492, Research Diets, New Brunswick,
NJ) from 4 weeks of age onward. Experimental animals
were weighed weekly up to 14 weeks of age. Mice were
fasted overnight by transferring to a new food-free
holding cage with unrestricted access to water, prior to
all experimental procedures. Care was taken to euthanize
all animals at 9 am (i.e. 3h into the light cycle, and at
similar times), and excised tissues were immediately
frozen in liquid nitrogen and then stored at  80 C. All
aspects of animal experimentation were approved by The
University of Queensland Animal Ethics Committee.
Microarray analysis
It is completely described in Supplementary Figure S1.
RNA extraction, cDNA synthesis and qPCR TLDA
analysis
Total RNA extraction and cDNA synthesis were per-
formed as described previously (4). We utilized custom
designed ABI microﬂuidic TLDAs to analyze the expres-
sion of genes involved in metabolism (lipid, carbohydrate
and energy homeostasis). Three control genes were
utilized, including the mandatory control (18S rRNA)
and four other controls: Gapdh, GusB, Hprt1 and 36B4.
These controls span the relative abundance/Ct range of
the genes on the card, and three (18S rRNA, GAPDH
and 36b4) are approved real time PCR controls for
NURSA supported nuclear receptor studies (15,16). The
TLDAs were analyzed as described in Myers et al. (17).
Brieﬂy, signiﬁcant changes in expression relative to wt
littermate mice were analyzed using the ABI/integromics
‘StatMiner’ software package. Diﬀerentially expressed
genes were identiﬁed by linear models (contained in the
LIMMA package for bioconductor R embedded in
StatMiner). Signiﬁcance was assigned by the application
of the Empirical Bayes statistic. B values represent the
empirical bayes log odds of diﬀerential expression, and
the t-value is the empirical bayes moderated t-statistic.
Subsequently, we applied a more stringent/conservative
data ﬁltering (Benjamini–Hochberg) to control for false
discovery rate, correct P values and further reﬁne the
subset of diﬀerentially expressed genes.
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Relative expression of genes was determined using the
ABI 7500 real time PCR System (ABI, Singapore) as pre-
viously described (3). Primers for LXRa, GAAATGCCA
GGAGTGTCGAC and GATCTGTTCTTCTGACAGC
ACACA; Akt1, GGCTGGCTGCACAAACG and GAC
TCTCGCTGATCCACATCCT; Akt3, CCTTCCAGAC
AAAAGACCGTTT and CGCTCTCTCGACAAATGG
AAA; GLUT1, TACGCTGGAGGCGGTAGCT and A
ATGGGCGAATCCTAAAATGG.
Protein extraction
Total soluble protein was extracted from skeletal muscle
(quadriceps) by the addition of lysis buﬀer (10mM Tris
(pH 8.0), 150mM NaCl, 1% Triton X-100 and 5mM
EDTA) containing protease and phosphatase ‘cocktail’
inhibitors (Roche diagnostics GmbH, Mannheim,
Germany). Lysates were passed through a 26-gauge
needle and centrifuged at 10000g for 20min. The super-
natant was collected and total protein concentration was
determined by the bicinchoninic acid (BCA assay kit),
as outlined by manufacturer’s instructions (Pierce
Biotechnology Inc., Rockford, IL, USA).
Glucose and insulin tolerance tests and glucose uptake
Basal glucose measurements were obtained from the tail
blood of overnight fasted animals (14–16 weeks of age).
Mice were then administered a dose of either glucose
solution (2g/kg) or insulin (0.5U/kg) by intraperitoneal
injection. Blood glucose measurements were obtained at
10 or 15min intervals for up to 90min following challenge
using the Accu-Chek Performa blood glucose testing
system (Roche Diagnostics Australia, Castle Hill, NSW).
Plasma insulin measurements were obtained using the
insulin (mouse) Ultrasensitive EIA (ALPCO Diagnostics,
Salem NH). Insulin-stimulated glucose uptake was per-
formed on skeletal muscle (extensor digitorum longus,
EDL) dissected from anesthetized mice and incubated in
essential buﬀer (Krebs–Henseleit, pH 7.4) and the assay
was performed as described previously (18,19).
Western blot analysis
Total soluble protein from the quadriceps of transgenic
and their littermate wild-type mice were resolved on a
10% SDS–PAGE gel and transferred to a PVDF
(Millipore Corporation, Billerica, MA, USA). The mem-
branes were blocked for 1h in 5% BSA in TBS–Tween 20,
followed by an overnight incubation with primary
antibody. The following antibodies were purchased from
Cell Signaling Technology, Danvers, MA and used at
1:1000 dilution: AMPKa (#2532), pAMPK (Thr172)
(#2535), Akt (#9272), pAKT (ser473) (#4058), ACC
(#3662) and pACC(Ser79) (#3661). Anti-GAPDH
(1:10000) was from R&D Systems, Minneapolis, MN.
Following 3 10min washes, the membrane was
incubated with anti-rabbit horseradish peroxidase (HRP)
(1:10000) for 1h. Immunoreactive signals were detected
using enhanced chemiluminescence Super Signal West
Pico Substrate (Pierce) and visualized by autoradiography
on an X-OMAT ﬁlm developer (Kodak).
Chromatin immunoprecipitation analysis
C2C12 cells were diﬀerentiated for 4 days. Cells were har-
vested and subsequently washed twice in ice cold PBS and
cross-linked in 1% formaldehyde solution. Chromatin
immunoprecipitation (ChIP) was performed as described
by Pearen et al. (20) using anti-RORa (Santa Cruz
anti-RORa sc-6062) and IgG (Santa Cruz, CA). The fol-
lowing qPCR ChIP primers were used: RORRE Site 1 F—
GCATGTGCTGCAAACATTCAG ( 2897 to  2876),
R—CTACACAGGGTCAGTGGCCA ( 2866 to
 2846). RORE Site 2F—GAACATGAAGATTTGAA
CTTG ( 2705 to  2684), R—CTGACCCAGAAACTC
CTACA ( 2668 to  2649). RORRE Site 3F—CTGGGT
CAGTAGAGTAGCAAGCC ( 2657 to 2634), R—TAA
GCATTCTGAGGTGACCTATGAA ( 2631 to 2606).
Downstream Negative control F—GTTCCCAAGTGAA
GAACCGC ( 278 to  258), R—CCGGCAATCAAAG
GGCTT ( 195 to  177).
Statistical analysis
The TLDA gene expression data were analyzed as
described above. All other results were analyzed (and sig-
niﬁcance assigned) using a t-test, or ANOVA in the
Graphpad Prism 4 software, unless otherwise indicated.
RESULTS
Overexpression of truncated RORa1"DE (lacking the
ligand-binding domain) in skeletal muscle
As discussed, RORa has been demonstrated to regulate
fat metabolism in several tissues. We were interested in
identifying and validating the (physiologically relevant)
in vivo functional role(s) and pathway(s) regulated by
RORa action in skeletal muscle. This major mass periph-
eral tissue accounts for  40% of the total body mass,
signiﬁcant levels of fatty acid oxidation, glucose disposal
and energy demand. We utilized the approach of
attenuating RORa signaling, by the targeted skeletal
muscle-speciﬁc expression of a truncated RORaDE
(lacking the ligand-binding domain) in transgenic mice,
to examine RORa action in this tissue. This approach
was utilized in the absence of the availability of a repro-
ducible and robust, native or synthetic agonist for the
modulation of this orphan nuclear receptor.
We produced transgenic mice (by pronuclear injection)
that selectively express a transgene encoding truncated
human RORa1 in skeletal muscle [under the control of
the human skeletal alpha actin promoter (10,11)]. The
transgene (RORa1DE) lacks the ligand-binding
domain and part of the hinge region, and encoded
amino acids 1–235 (6). McBroom et al. (21) reported
that deletion of this segment preserved DNA recognition
and binding, suppressed trans-activation and operated in
a dominant negative manner. In addition, Hamilton et al.
(22) reported the staggerer mutation is located in a similar
position, and produces a non-functional ligand-binding
4298 Nucleic Acids Research, 2010,Vol.38, No. 13domain. Moreover, we previously demonstrated in an
in vitro myogenic cell culture model that this construct
attenuated RORa mediated trans-activation, and ectopic
expression suppressed endogenous RORa mRNA expres-
sion (3).
We observed that the heterozygous transgenic mice pre-
dominantly (and abundantly) expressed the ectopic tran-
script (transgene) in skeletal muscle relative to other
organ/tissues (cerebellum, spleen, heart, white adipose,
liver and pancreas; Figure 1A and B). Heart and brain
expressed <2% of the ectopic transcript, relative to ex-
pression in skeletal muscle. This was consistent with
several other studies that utilized this promoter in trans-
genic models (10,12,23). Quantitative real-time PCR
(q-PCR) analysis of mRNA expression demonstrated
that the ectopic truncated RORa transcript was expressed
between 3- and 4-fold higher than the endogenous RORa
transcript in the muscle of transgenic mice (Figure 1A). As
expected, the ectopic RORa transcript was not detectable
in wt littermates (data not shown). Concordantly, expres-
sion analysis demonstrated that total (endogenous plus
ectopic) RORa transcript expression increased  3-fold
in the muscle of transgenic, relative to wt littermate mice
(Figure 1C). In this background we observed a decrease
(that did not attain signiﬁcance) in the levels of total en-
dogenous RORa1 and 4 mRNA expression in the muscle
of transgenic relative to wt littermate mice (Figure 1D).
Surprisingly, isoform-speciﬁc q-PCR analysis of RORa1
and RORa4, revealed signiﬁcant suppression of RORa1
(but not a4) mRNA expression (Figure 1E and F). Staels
(1,5) and our group (3,8) amongst others have previously
demonstrated that the a1 isoform has a physiological role
in the regulation of lipid homeostasis. To further charac-
terize the line of mice, we examined expression of a bona
ﬁde RORa (1 and 4) target gene, apolipoprotein A5,
characterized by two independent groups (24,25), which
was very signiﬁcantly decreased in the Tg-RORa1DE
mice (Figure 1G). These data demonstrate the line of
Tg-RORa1DE mice, express the ectopic transcript,
suppress endogenous RORa1 mRNA expression and at-
tenuate RORa1-dependent gene expression.
Expression proﬁling of skeletal muscle from the
RORa1"DE mice: identiﬁcation of functions and
pathways
To rigorously identify the in vivo functional role(s), and
pathway(s) regulated by RORa action in skeletal muscle,
we carried out expression proﬁling coupled to functional
and signaling characterization by Ingenuity pathway
analysis (Supplementary Figures S2–S5). Using a P
value cut-oﬀ of P<0.05 and a fold change cut oﬀ of
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Figure 1. (A) qPCR of the ectopic transgene gene (hRORa1DE) and endogenous RORa expression in various tissue/organs in heterozygous
transgenic mice. Relative mRNA expression is normalized against 18S mRNA (n=6/group, mean±SEM, ***P<0.001). (B) qPCR of the ectopic
transgene gene (hRORa1DE) in pancreas versus skeletal muscle from wild-type and heterozygous transgenic mice. Relative mRNA expression is
normalized against 18S mRNA (n=6/group). (C) qPCR of total RORa (ectopic and endogenous) in skeletal muscle of wild-type and transgenic
mice. Relative fold change of (mRNA expression) is normalized against 18S mRNA (n=6/group, mean±SEM, ***P<0.001). qPCR of (D)
endogenous RORa1 and 4; (E) endogenous RORa1andF)endogenous RORa4 mRNA expression in skeletal muscle of wild-type and transgenic
mice. Relative fold change of (mRNA expression) is normalized against 18S mRNA (n=6/group, mean±SEM), *P<0.05. (G) qPCR of ApoA5
mRNA expression in skeletal muscle of wild-type and transgenic mice. Relative fold change of (mRNA expression) is normalized against 18S mRNA
(n=6/group, mean±SEM, ***P<0.001).
Nucleic Acids Research, 2010,Vol.38, No. 13 42991.3, the top 50 annotated genes that were diﬀerentially up-
and down-regulated in a signiﬁcant manner are shown in
Tables 1 and 2, respectively [the complete list of genes
(including the non-annotated genes) is shown in
Supplementary Figure S2. In concordance with the
overexpression of a dominant negative, the expression
proﬁling, Genespring and Ingenuity analysis identiﬁes a
majority of genes in the down regulated category, and
the bulk of highly ranked functions and pathways
were attenuated/suppressed (This is evident in the
complete list of genes in Supplementary Figure S2 and
in the graphical representations of the data in
Supplementary Figures S3–S5).
Interrogation of diﬀerentially expressed genes on the
Ingenuity platform identiﬁed that a subset of diﬀerentially
expressed genes in Tg-RORa1DE mice were involved
in/associated with lipid metabolism, small molecule trans-
port and biochemistry, cardiovascular and metabolic
disease, carbohydrate metabolism, endocrine system dis-
orders etc (see Supplementary Figure S4), in concordance
with the pathophysiological role of NRs. The majority of
metabolic genes are down regulated in the major function-
al categories of lipid and carbohydrate metabolism
(Supplementary Figure S4 and S5). This is consistent
with several investigations in RORa deﬁcient mouse
models(2,8). In the framework of this investigation, the
primary signaling pathways regulated in skeletal muscle
were the glutathione metabolism (responsible for the
tight control of ROS levels, which modulate insulin sensi-
tivity), type 2 diabetic signaling and fatty acid
Table 1. Downregulated annotated genes in RORa1DE
Symbol Gene name Fold change P-value Accession number
Ucp1 Uncoupling protein 1 34.89 0.000 NM_009463.2
Fasn Fatty acid synthase 8.96 0.001 NM_007988.3
Cidea Cell death-inducing DNA fragmentation factor, alpha subunit-like eﬀector A 8.58 0.000 NM_007702.1
Scd1 Stearoyl-Coenzyme A desaturase 1 5.47 0.004 NM_009127.3
Hp Haptoglobin 4.22 0.004 NM_017370.1
Prkar2b Protein kinase, camp dependent regulatory, type II beta 4.06 0.004 NM_011158.3
Apoc1 Apolipoprotein C-I 3.11 0.006 NM_007469.2
Igh-6 Immunoglobulin heavy chain 6 (heavy chain of IgM) 2.93 0.014 XM_354710.1
Fah Fumarylacetoacetate hydrolase 2.72 0.008 NM_010176.1
Tmem45b Transmembrane protein 45b 2.62 0.000 NM_144936.1
Elovl6 ELOVL family member 6, elongation of long chain fatty acids 2.47 0.000 NM_130450.2
Myo1e Myosin IE 2.43 0.010 NM_181072.3
Ces3 Carboxylesterase 3 2.21 0.001 NM_053200.2
Sfxn1 Sideroﬂexin 1 2.11 0.013 NM_027324.2
Acaca Acetyl-coenzyme A carboxylase alpha 2.02 0.002 NM_133360.2
Rab15 RAB15, member RAS oncogene family 2.00 0.008 NM_134050.2
Cox6a1 Cytochrome c oxidase, subunit VI a, polypeptide 1 2.00 0.000 NM_007748.3
Tkt Transketolase 1.97 0.004 NM_009388.2
Fgfbp1 Fibroblast growth factor binding protein 1 1.90 0.006 NM_008009.3
Thrsp Thyroid hormone responsive SPOT14 homolog 1.90 0.006 NM_009381.2
Sfxn1 Sideroﬂexin 1 1.90 0.010 NM_027324.2
Cox6a1 Cytochrome c oxidase, subunit VI a, polypeptide 1 1.86 0.000 NM_007748.3
D12Ertd647e DNA segment, Chr 12, ERATO Doi 647, expressed, transcript variant 4 1.85 0.006 NM_194068.1
Agpat2 1-Acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta) 1.84 0.000 NM_026212.1
Pygl Liver glycogen phosphorylase 1.84 0.000 NM_133198.1
Ehhadh Enoyl-coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase 1.83 0.007 NM_023737.2
Aoc3 Amine oxidase, copper containing 3 1.81 0.012 NM_009675.1
M6prbp1 Mannose-6-phosphate receptor binding protein 1 1.81 0.003 NM_025836.1
Idh1 Isocitrate dehydrogenase 1 (NADP
+), soluble 1.79 0.007 NM_010497.2
Atp1b4 Atpase, (Na
+)/K
+ transporting, beta 4 polypeptide 1.78 0.000 NM_133690.2
Exod1 Exonuclease domain containing 1 1.77 0.012 NM_027698.3
Hsd17b12 Hydroxysteroid (17-beta) dehydrogenase 12 1.76 0.002 NM_019657.2
Wnt4 Wingless-related MMTV integration site 4 1.76 0.004 NM_009523.1
Cebpa CCAAT/enhancer binding protein 1.75 0.005 NM_007678.2
Slc27a2 Solute carrier family 27 (fatty acid transporter), member 2 1.73 0.009 NM_011978.2
Apoc1 Apolipoprotein C-I 1.72 0.013 NM_007469.2
Tmcc3 Transmembrane and coiled coil domains 3 1.71 0.004 NM_172051.2
Zfp691 Zinc ﬁnger protein 691 1.71 0.000 NM_183140.1
Olfm1 Olfactomedin 1, transcript variant 2 1.68 0.010 NM_001038612.1
Gnao1 Guanine nucleotide binding protein, alpha o 1.68 0.007 NM_010308.3
Gcat Glycine C-acetyltransferase (2-amino-3-ketobutyrate coenzyme A ligase) 1.67 0.012 NM_013847
Abhd8 Abhydrolase domain containing 8 1.64 0.005 NM_022419.1
Pparg Peroxisome proliferator activated receptor gamma 1.64 0.001 NM_011146.1
Cox8a Cytochrome c oxidase, subunit viiia 1.63 0.001 NM_007750.2
Tspo Translocator protein 1.62 0.001 NM_009775.2
Lrtm1 Leucine-rich repeats and transmembrane domains 1 1.62 0.001 NM_176920.2
Igh-1a Immunoglobulin heavy chain 1a 1.62 0.002 XM_354704.1
Slc16a10 Solute carrier family 16 (monocarboxylic acid transporters), member 10 1.62 0.001 NM_028247.1
Tspo Translocator protein 1.60 0.003 NM_009775.2
Hsd11b1 Hydroxysteroid 11-beta dehydrogenase 1, transcript variant 2 1.60 0.001 NM_001044751.1
4300 Nucleic Acids Research, 2010,Vol.38, No. 13biosynthesis. Notably, several NR signaling (and
RXR-dependent) pathways including LXR, FXR VDR
and PXR were identiﬁed in the analysis. The higher
ranked NR signaling pathways control lipogenesis/fatty
acid biosynthesis (LXR) and cholesterol homeostasis
(LXR and FXR) in agreement with the functional anno-
tation (see Supplementary Data S4 and S5). The majority
of diﬀerentially expressed genes were associated with lipid/
carbohydrate metabolism and metabolic disease
(Supplementary Data S5A).
Expression of the truncated orphan nuclear receptor,
RORa, aﬀected the fatty acid biosynthetic pathway:
decreased SREBP-1c, LXRa and downstream target
genes in Tg-RORa1"DE mice
Previously we have demonstrated that staggerer mice
(sg/sg), with decreased and dysfunctional RORa expres-
sion (in all organs) are resistant to (high fat) diet induced
obesity (8). The genes, pathways and functional role
identiﬁed (for RORa) from the interrogation of the data
revealed that lipid metabolism (especially fatty acid
Table 2. Upregulated annotated genes in RORa1DE
Symbol Gene name Fold change P-value Accession number
Zranb3 Zinc ﬁnger, RAN-binding domain containing 3 2.64 0.000 NM_172642.1
Rom1 Rod outer segment membrane protein 1 2.54 0.000 NM_009073.2
Tceal5 Transcription elongation factor A (SII)-like 5 2.43 0.001 NM_177919.1
Col7a1 Procollagen, type VII, alpha 1 2.21 0.010 NM_007738.3
Plekhb1 Pleckstrin homology domain containing, family B (evectins) member 1 2.10 0.001 NM_013746.1
Tnfrsf22 Tumor necrosis factor receptor superfamily, member 22 2.10 0.001 NM_023680.2
Tnfrsf22 Tumor necrosis factor receptor superfamily, member 22 1.94 0.001 NM_023680
Gfer Growth factor, erv1 (S. cerevisiae)-like (augmenter of liver regeneration) 1.90 0.000 NM_023040.3
Tob1 Transducer of erbb-2.1 1.79 0.011 NM_009427.2
Stab2 Stabilin 2 1.79 0.001 NM_138673.1
Camk2n2 PREDICTED: calcium/calmodulin-dependent protein kinase II inhibitor 2 1.77 0.003 XM_993468.1
Il17re Interleukin 17 receptor E, transcript variant 2 1.71 0.001 NM_001034029.1
Lgals1 Lectin, galactose binding, soluble 1 1.61 0.000 NM_008495.2
Slc22a4 Solute carrier family 22 (organic cation transporter), member 4 1.61 0.007 NM_019687.3
Ush1c Usher syndrome 1C homolog, transcript variant a1 1.59 0.008 NM_023649.1
Maged2 Melanoma antigen, family D, 2 1.55 0.003 NM_030700.1
Gdf11 Growth diﬀerentiation factor 11 1.52 0.007 NM_010272.1
Sfxn3 Sideroﬂexin 3 1.50 0.010 NM_053197.2
Rab11ﬁp5 RAB11 family interacting protein 5 (class I), transcript variant 2 1.50 0.009 NM_177466.4
Synpo2l Synaptopodin 2-like 1.50 0.008 NM_175132.3
Hes1 Hairy and enhancer of split 1 1.49 0.001 NM_008235.2
Actr1b ARP1 actin-related protein 1 homolog B, centractin beta (yeast) 1.47 0.001 NM_146107
Actr1b ARP1 actin-related protein 1 homolog B 1.47 0.007 NM_146107.2
Rala V-ral simian leukemia viral oncogene homolog A (ras related) 1.47 0.004 NM_019491.5
Sms Spermine synthase 1.46 0.000 NM_009214.3
C1qtnf4 C1q and tumor necrosis factor related protein 4 1.44 0.006 NM_026161.1
Sorl1 Sortilin-related receptor containing LDLR class A repeats 1.42 0.009 NM_011436
Des Desmin 1.42 0.004 NM_010043.1
Nans N-acetylneuraminic acid synthase (sialic acid synthase) 1.40 0.002 NM_053179.2
Ccl25 Chemokine (C-C motif) ligand 25 1.40 0.002 NM_009138.1
Rrm1 Ribonucleotide reductase M1 1.39 0.002 NM_009103
Eif1ay Eukaryotic translation initiation factor 1A, Y-linked 1.39 0.012 NM_025437
Setd8 SET domain containing (lysine methyltransferase) 8 1.38 0.007 NM_030241.2
Igfbp5 Insulin-like growth factor binding protein 5 1.37 0.000 NM_010518
Mllt3 Myeloid/lymphoid or mixed lineage-leukemia translocation to 3 homolog
(Drosophila), transcript variant 2
1.36 0.008 NM_029931.2
Zbtb12 Zinc ﬁnger and BTB domain containing 12 1.35 0.012 NM_198886.2
Smarcd3 SWI/SNF related, matrix associated, actin-dependent regulator of chromatin,
subfamily d, member 3
1.35 0.006 NM_025891.3
Hdac4 Histone deacetylase 4 1.35 0.000 NM_207225.1
Eif3s2 Eukaryotic translation initiation factor 3, subunit 2 (beta) 1.35 0.002 NM_018799.1
St3gal2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2, transcript variant 2 1.34 0.006 NM_178048.2
Slc25a15 Solute carrier family 25 (mitochondrial carrier ornithine transporter), member 15 1.34 0.000 NM_181325.2
Klc2 Kinesin light chain 2 1.34 0.007 NM_008451
Epdr1 Ependymin-related protein 1 1.34 0.012 NM_134065.2
Slc11a2 Solute carrier family 11 (proton-coupled divalent metal ion transporters),
member 2
1.34 0.010 AK049856
Abca15 ATP-binding cassette, subfamily A (ABC1), member 15 1.34 0.006 NM_177213.3
Pip5k2b Predicted: phosphatidylinositol-4-phosphate 5-kinase, type II, beta, transcript
variant 4
1.33 0.003 XM_991639.1
Ptp4a2 Protein tyrosine phosphatase 4a2 1.33 0.003 NM_008974.3
Col11a2 Procollagen, type XI, alpha 2 1.33 0.006 NM_009926.1
Prkcq Protein kinase C, theta 1.32 0.014 NM_008859.2
Ssbp2 Single-stranded DNA-binding protein 2 1.32 0.012 NM_024186.1
Nucleic Acids Research, 2010,Vol.38, No. 13 4301biosynthesis/lipogenesis) functions and pathways were
highly ranked. We have validated the illumina/genespring
analysis by rigorous qPCR analysis utilizing a
custom-designed ABI microﬂuidic TLDA, that encoded
taqman primer sets for critical metabolic genes involved
in the control of lipid homeostasis. Speciﬁcally, in the
context of lipogenic gene expression, TLDA analysis
revealed signiﬁcant diﬀerential expression (normalized
against 18S rRNA) of the mRNAs encoding acyl-CoA
synthetase long chain family member 4 (ACSL4), fatty
acid translocase/cluster of diﬀerentiation 36 (FAT/
CD36), fatty acid synthase (FAS), stearyl-coA dehydro-
genase 1 (SCD-1), SREBP-1c and many other genes in the
skeletal muscle of male Tg-RORa1DE mice relative to
wild-type littermates (assigned by the Empirical Bayes
statistic, see Table 3, Supplementary Data S6—
Supplementary Figure S6 shows the complete list).
Stringent ﬁltering of data using the Benjamini–Hochberg
method to control P value false discovery rate (FDR)
reﬁned the signiﬁcant subset of diﬀerentially expressed
genes to SREBP-1c, FAS, SCD-1, ACSL4, CD36 and
HIF1a (Figure 2A and Table 3).
Subsequently, we used (manual) qPCR to examine (and
validate) the expression of several other genes in the lipo-
genic pathway that were identiﬁed in the illumina analysis
as signiﬁcant, diﬀerentially expressed targets. The
Tg-RORa1DE mice also displayed signiﬁcantly
reduced expression of the mRNAs encoding the nuclear
hormone receptor, LXRa (Figure 2B), a critical transcrip-
tional regulator of SREBP-1c and the genetic program
that regulates lipogenesis. Interestingly, the expression of
both FAS and SCD-1 (responsible for the synthesis of
de novo fatty acids and monounsaturated fatty acids,
respectively) was also decreased. These genes are down-
stream targets of LXRa and SREBP1c (the master tran-
scriptional regulators of the genetic program that
Table 3. Relative quantiﬁcation of gene expression in skeletal muscle of transgenic compared to wt littermate controls
Entrez gene symbol-
TaqMan assay ID
Ct P-value B-value t-value RQ. Log10 RQ. Linear Signiﬁcance Adj. P-value Signiﬁcance FDR
Lipogenesis
a
Abca1-Mm00442646_m1 0.628 0.038  4.081 2.283  0.189 0.647 Signiﬁcant 0.080 NS
Acsl4-Mm00490331_m1 1.396 0.001  0.313 4.273  0.420 0.380 Signiﬁcant 0.012 Signiﬁcant
Cav3-Mm01182632_m1 0.452 0.043  4.190 2.220  0.136 0.731 Signiﬁcant 0.081 NS
Cd36-Mm00432403_m1 1.115 0.013  3.121 2.814  0.335 0.462 Signiﬁcant 0.042 Signiﬁcant
Cebpb-Mm00843434_s1 0.908 0.023  3.614 2.546  0.273 0.533 Signiﬁcant 0.061 NS
Cebpd-Mm00786711_s1 1.086 0.029  3.827 2.428  0.327 0.471 Signiﬁcant 0.068 NS
Fasn-Mm00662319_m1 1.844 0.005  2.163 3.316  0.555 0.279 Signiﬁcant 0.023 Signiﬁcant
Hif1a-Mm00468875_m1 0.797 0.013  3.082 2.834  0.240 0.575 Signiﬁcant 0.042 Signiﬁcant
Scd1-Mm00772290_m1 2.099 0.001  0.881 3.978  0.632 0.233 Signiﬁcant 0.012 Signiﬁcant
Srebf1-Mm00550338_m1 0.764 0.004  2.034 3.383  0.230 0.589 Signiﬁcant 0.023 Signiﬁcant
Nuclear receptors
b
Nr1h3-Mm00443454_m1 0.814 0.039  3.531 2.522  0.245 0.569 Signiﬁcant 0.393 NS
Nr2c1-Mm00449123_m1 0.601 0.032  3.353 2.661  0.181 0.659 Signiﬁcant 0.393 NS
Nr3c1-Mm00433832_m1 0.912 0.005  1.734 4.037  0.275 0.531 Signiﬁcant 0.234 NS
Ppard-Mm00803186_g1 0.926 0.041  3.564 2.496  0.279 0.526 Signiﬁcant 0.393 NS
Rorc-Mm00441139_m1 0.860 0.019  2.911 3.013  0.259 0.551 Signiﬁcant 0.393 NS
Glucose homeostasis
a
Akt2-Mm00545827_m1 1.684 0.001  0.621 4.337  0.507 0.311 Signiﬁcant 0.037 Signiﬁcant
Cs- Mm00466043_m1 0.515 0.011  2.781 3.061  0.155 0.700 Signiﬁcant 0.087 NS
Foxo1-Mm00490672_m1 1.229 0.042  4.074 2.295  0.370 0.427 Signiﬁcant 0.173 NS
Il15-Mm00434210_m1 1.076 0.026  3.634 2.561  0.324 0.474 Signiﬁcant 0.132 NS
Lepr-Mm00440181_m1 1.173 0.009  2.664 3.129  0.353 0.443 Signiﬁcant 0.087 NS
Pdk3-Mm00455220_m1 1.071 0.028  3.703 2.520  0.323 0.476 Signiﬁcant 0.132 NS
Pdk4-Mm00443325_m1 0.887 0.018  3.293 2.763  0.267 0.541 Signiﬁcant 0.119 NS
Stat5b-Mm00839889_m1 0.892 0.003  1.646 3.723  0.269 0.539 Signiﬁcant 0.053 NS
Myogenesis
a
Acvr2a-Mm00431657_m1 0.616 0.029  3.719 2.502  0.185 0.653 Signiﬁcant 0.123 NS
Gdf8-Mm00440328_m1 0.888 0.047  4.155 2.234  0.267 0.540 Signiﬁcant 0.141 NS
Hdac5-Mm00515917_m1 0.599 0.001  0.721 4.283  0.180 0.660 Signiﬁcant 0.026 Signiﬁcant
Mef2a-Mm00488969_m1 0.397 0.042  4.061 2.293  0.119 0.760 Signiﬁcant 0.140 NS
Mef2d-Mm00504929_m1 0.499 0.021  3.398 2.693  0.150 0.708 Signiﬁcant 0.114 NS
Smad1-Mm00484721_m1 0.503 0.034  3.847 2.424  0.151 0.706 Signiﬁcant 0.123 NS
Smad2-Mm00487530_m1 0.701 0.011  2.793 3.050  0.211 0.615 Signiﬁcant 0.087 NS
Tgfbr1-Mm00436971_m1 1.296 0.002  0.925 4.157  0.390 0.407 Signiﬁcant 0.026 Signiﬁcant
Tgfbr2-Mm00436978_m1 0.675 0.013  2.977 2.941  0.203 0.626 Signiﬁcant 0.087 NS
Tnni2-Mm00437157_g1 0.510 0.009  2.561 3.185  0.154 0.702 Signiﬁcant 0.087 NS
Signiﬁcance was assigned by the application of the Empirical Bayes statistic. RQ, relative quantiﬁcation; FDR, false detection rate; NS, not
signiﬁcant. Bold text denotes signiﬁcant changes in gene expression after more conservative data ﬁltering (Benjamini-Hochberg) to control for
false discovery rate, and correct P-values.
aTarget genes normalized to 18S RNA.
bTarget genes normalized to gusB, hprt1 and gapdh.
4302 Nucleic Acids Research, 2010,Vol.38, No. 13modulates lipogenesis). Moreover, these changes in gene
expression were not observed in either liver or adipose
tissue (data not shown).
In addition, we analyzed several genes that are involved
in intramuscular triglyceride (IMTG) accumulation.
We identiﬁed that the expression of the two mRNAs
encoding tail interacting protein (Tip47) and di-acyl
glycerol acetyl transferase 2 (Dgat2) were signiﬁcantly
reduced in the male Tg-RORa1DE transgenic mice
relative to wild-type littermate pairs (Figure 2C and D).
In summary, we observed qPCR validation of the master
transcriptional regulators of fatty acid biosynthesis (LXR
and SREBP-1c) and several important downstream target
genes (including FAS and SCD-1).
The observation of attenuated LXR expression and
decreased downstream target gene expression was consist-
ent with the identiﬁcation of this NR signaling cascade in
the pathway analysis (Supplementary Figures S4 and S5).
We explored the NR signaling pathways more rigorously
by performing qPCR analysis utilizing a custom-designed
ABI microﬂuidic TLDA that encoded taqman primer sets
targeting all 48 mouse NRs. The analysis revealed small,
but signiﬁcantly reduced (1.5–2.5-fold) expression of the
mRNAs encoding the nuclear hormone receptors: LXRa,
TR2, PPARd, GR and RORg in the Tg-RORa1DE
mice, relative to the wt littermates (Figure 2E, Table 3
and Supplementary Figure S7 shows the complete list of
nuclear hormone receptors). Please note increased RORa
expression in the Tg-RORaDE was not detected because
the TLDA was mouse speciﬁc and the transgenic line ex-
pressed the truncated human transcript.
In summary, parallel analysis by illumina, ingenuity and
qPCR on the TLDA platform have demonstrated that
RORa in skeletal muscle leads regulates the lipogenic/
fatty acid biosynthetic pathway.
Expression of truncated RORa attenuated Akt (mRNA
and protein) expression in Tg-RORa1"DE mice
Pathway analysis revealed the involvement of RORa
expression in carbohydrate metabolism and type 2
diabetic signaling, and that truncated RORa expression
eﬀected Akt2 mRNA levels (Supplementary Figures S2,
S4 and S5A). This led us to further examine the expression
of critical genes involved in carbohydrate metabolism
using the custom-designed ABI microﬂuidic TLDA to
perform qPCR analysis. We identiﬁed statistically signiﬁ-
cant diﬀerential expression of several important genes that
control insulin signaling and glucose uptake (Table 3,
Supplementary Figure S8 shows the complete list of
genes analyzed) in the Tg-RORa1DE mice, relative to
wild-type littermates. TLDA analysis revealed the expres-
sion of the mRNAs encoding Akt2, pyruvate dehydrogen-
ase kinase isozyme 3 and 4 (Pdk3 and 4), and several other
genes were signiﬁcantly reduced in the skeletal muscle of
male Tg-RORa1DE mice relative to wild-type
littermates (see Table 3, Supplementary Figure S8.
Subsequently, after correction/adjustment of P values ac-
cording to the Benjamini–Hochberg FDR method, Akt2
remained the only transcript that was signiﬁcantly and
diﬀerentially expressed (and repressed) in the
Tg-RORa1DE line (see Table 3, Supplementary Figure
S8 and Figure 3A). It should be noted that the data (prior
to FDR ﬁltering) has been derived from sensitive qPCR
TLDA analysis from six littermate pairs of mice focused
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Figure 2. Graphs showing signiﬁcant changes in expression of lipogen-
ic genes in the skeletal muscle of transgenic mice. (A) Data derived
from Table 3 are expressed as fold change (log10) normalized to 18S
mRNA, following application of Benjamini–Hochberg false detection
rate algorithm. qPCR of (B) LXRa,( C) Tip47 and (D) Dgat2 in
skeletal muscle of transgenic and wt littermate control mice. Relative
fold change is normalized against 18S mRNA (n=6/group,
mean±SEM. *P<0.05, **P 0.01 ***P 0.001). (E) Graphs
showing signiﬁcant changes in expression of the entire NR gene super-
family in the skeletal muscle of transgenic mice. Data derived from
Table 3 and S7 are expressed as fold change (log10) after normalization
against the median of three genorm-selected controls GAPDH, gusB
and Hprt1 following application of Benjamini–Hochberg false detection
rate algorithm.
Nucleic Acids Research, 2010,Vol.38, No. 13 4303on metabolic genes. Assignment of signiﬁcance prior to
application of FDR analysis is relatively robust.
Subsequently, we also assessed the expression of the
other Akt family members. Although Akt2/PKB was sig-
niﬁcantly decreased in the skeletal muscle of male
Tg-RORa1DE mice relative to wild-type littermates,
we observed no change in the expression of the mRNAs
encoding, Akt1 or 3 (data not shown). Notably, no sig-
niﬁcant changes in gene expression were observed in either
liver or adipose tissue after TLDA analysis (data not
shown). In addition, we investigated whether attenuation
in Akt2 mRNA expression correlated with changes in the
protein levels of total Akt and phosphorylated (ser473)
Akt/PKB using western analysis (Figure 3B). We
observed a signiﬁcant decrease in total Akt/PKB protein
in the Tg-RORa1DE mice relative to wild-type
littermate pairs (Figure 3B and C), corresponding with
the mRNA expression data. Moreover, the levels of the
active phosphorylated (ser473) Akt species were also sig-
niﬁcantly decreased (Figure 3B and D). Akt/PKB is a
critical target in the regulation of GLUT4-[solute carrier
family 2a (facilitated glucose transporter), member 4]
mediated glucose uptake. In summation, corresponding
investigation by illumina, qPCR (on the TLDA
platform) and western analysis have demonstrated that
RORa in skeletal muscle regulates Akt2 mRNA, protein
and phosphorylation. This is consistent with the high
ranking of carbohydrate metabolism and type 2 diabetic
signaling by the ingenuity platform.
Expression of truncated RORa in skeletal muscle induced
mild hyperglycemia and glucose intolerance: attenuated
insulin-mediated phosphorylation of Akt in the
Tg-RORa1"DE mice
Suppression of (total and phospho) Akt in skeletal muscle
suggests the mouse model may display increased plasma
glucose and impaired glucose tolerance. We conducted
several experiments to characterize the phenotypic (and
metabolic eﬀects) of aberrant RORa expression in
skeletal muscle to validate the results of the illumina/in-
genuity analysis.
The transgenic mice presented with no gross or histo-
logical phenotypic abnormalities, although they did
appear to be slightly smaller than their wt littermates.
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Figure 3. (A) Graph showing a signiﬁcant fold repression of Akt2 (RQ_Log10) in insulin-stimulated glucose uptake after stringent ﬁltering of data
by the application of Benjamini–Hochberg false detection rate algorithm.In the skeletal muscle of transgenic mice relative wild-type mice. Data are
derived from Table 3 and is expressed as fold change (log10) normalized to 18S mRNA, following application of Benjamini–Hochberg false detection
rate algorithm (n=6/group) (B) western blot analysis of Akt and pAkt in skeletal muscle of male transgenic mice and wt littermate control mice.
Densitometry analysis of western blots (C) Akt and (D) pAkt (n=3/group, mean±SEM. *P<0.05, **P 0.01). (E) Body weight development in
transgenic mice versus wt littermate controls over 14 weeks on normal chow diet (n=19 male and n=6 female, mean±SEM. *P<0.05).
(F) Plasma glucose levels of overnight fasted male transgenic and wt littermate control mice (n=6/group, mean±SEM. *P<0.05). (G) Blood
glucose concentrations measured at various times after I/P administration of glucose (t=0) to overnight fasted male transgenic and wt littermate
control mice (n=7/group, mean±SEM. *P<0.05, **P 0.01). (H) Blood glucose concentrations measured at various times after IP administration
of insulin (t=0) to overnight fasted male transgenic and wt littermate control mice. Data are presented as percentage of starting blood glucose
concentration at time=0 (I=7/group, mean±SEM).
4304 Nucleic Acids Research, 2010,Vol.38, No. 13However, growth curve analysis from 4 to 14 weeks indi-
cates that both male and female Tg-RORa1DE mice on
a regular chow diet showed no signiﬁcant reductions in
body weight, relative to wild-type littermate pairs
(Figure 3E). All subsequent studies were performed on
male mice.
We subsequently measured blood glucose and observed
mild hyperglycemia in the transgenic mice, with increased
fasting glucose levels in male transgenic mice relative
to wild-type littermate pairs (Figure 3F). This is consistent
with decreased (total and phospho) Akt (mRNA
and protein) levels in skeletal muscle. We further
examined systemic glucose metabolism, and performed
intraperitoneal glucose and insulin tolerance tests. In the
Tg-RORa1DE mice, glucose clearance was signiﬁcantly
delayed following a glucose challenge (Figure 3G). No
signiﬁcant diﬀerences in plasma insulin levels between
the transgenic and wt mice (on regular chow diets) were
detected (data not shown). Furthermore, the glucose ex-
cursions displayed by Tg-RORa1DE compared to
wild-type mice during an insulin tolerance test were com-
parable (Figure 3H). Moreover, no diﬀerences in plasma
insulin concentration were observed either at baseline or
ten minutes subsequent to glucose administration (data
not shown).
We subsequently examined whether skeletal muscle-
speciﬁc expression of Tg-RORa1DE mice played a
role in insulin signaling. Protein extracts were
isolated from saline and insulin injected (littermate pairs
of) wt and Tg mice and subsequently analyzed by
immunoblot analysis using Ab’s speciﬁc to Akt2 and
phospho- Akt2.
Quantiﬁcation of the western blots (Figure 4E and F)
demonstrated that there were no signiﬁcant diﬀerences in
(basal) total Akt2 levels in between saline and insulin-
treated wild-type and Tg animals. As expected, insulin
treatment in wild-type mice signiﬁcantly stimulated the
levels of phosphoS473Akt2 relative to saline treated
mice ( 3-fold Figure 4A and B). However, we observed
that insulin treatment did not signiﬁcantly increase phos-
phorylation of Akt Ser473 in the male Tg-RORa1DE
mice (Figure 4C and D, respectively).
Furthermore, impaired glucose tolerance and insulin
stimulation of Akt phosphorylation did not involve (or
result in) signiﬁcant changes in GLUT 2, 4 or 8 mRNA
expression (determined by qPCR-microﬂuidic TLDA
analysis, see Supplementary Figure S7). GLUT1 mRNA
expression was analyzed independently by qPCR, and
data presented as a footnote in Supplementary Figure
S8. The expression of the mRNAs encoding Glut1, 4
and 8 was decreased by  20%, however, after Bayes
and FDR analysis, these changes did not attain signiﬁ-
cance (Supplementary Figure S8).
In the context of the hyperglycemia, impaired glucose
tolerance and insulin stimulation of Akt phosphorylation,
we investigated whether ex vivo glucose uptake was
aﬀected by transgenic RORDE expression.
(Figure 4E). In wild-type type 2 (fast twitch glycolytic
EDL, Figure 4E) skeletal muscle, glucose uptake was
increased  2-fold by insulin treatment. Similar results
were observed in soleus muscle (data not shown).
In contrast, in the Tg-RORa1DE mice, glucose uptake
did not signiﬁcantly respond to insulin treatment
(Figure 4E).
To further explore the molecular basis of aberrant Akt2
mRNA, protein and phospho AKt expression in the trans-
genic Tg-RORa1DE mice, we examined the mouse Akt2
promoter sequence (as reported on the Ensembl site) for
putative RORE elements. Interestingly, we identiﬁed
three putative ROR response elements (RORREs)
between nucleotide positions,  2900 to  2600bp
upstream of the transcription start site that were concord-
ant with the optimal RORa1 binding site,
R=A
Y=A
T=A
T=R
T=A
Y=TRGGTCA as described by Giguere
et al., (26). (Figure 5A and B). In order to determine
whether RORa was selectively recruited to the putative
ROR responsive elements (NR1, 2 and 3) within the
mouse Akt2 promoter, we designed three sets of pri-
mers and one set of negative primers downstream of
the putative sites within the promoter (Figure 5)
for ChIP in skeletal muscle cells. It was observed that
the RORa antibody [using anti-RORalpha (Santa Cruz
anti-RORa sc-6062)] eﬀectively immunoprecipitated
the NR1 ( 2859/ 2853) and NR2 ( 2655/ 2649
[and to a lesser extent the NR3 ( 2626/2620)] motifs
relative to IgG, and the no antibody controls
(Figure 5C). The speciﬁcity of RORalpha recruitment to
these NR half sites was underscored by the lack of recruit-
ment, i.e. the failure to immunoprecipitate the negative
control region further downstream between nucleotide
positions  278/ 177 [ 1.6-kb downstream of these
putative RORE sites, (Figure 5C)]. In summary, these
data clearly demonstrate that RORa is recruited directly
to the mouse Akt2 promoter, and suggest the direct func-
tional involvement of RORa1 in the regulation of AKt2
expression.
In summary, parallel analysis by illumina, ingenuity,
qPCR and western and metabolic analysis has
demonstrated that RORa expression in skeletal muscle
regulates Akt expression (and phosphorylation state),
blood glucose levels, glucose tolerance and insulin-
stimulated Akt2 phosphorylation and glucose uptake.
Reduced Akt correlates with increased levels of phospho
(thr172)-adenosine monophosphate kinase in
Tg-RORa1"DE mice
Recent research has demonstrated that Akt2/PKB is a
potent negative regulator of AMPK activity (Figure 6A)
in murine cardiac muscle and ﬁbroblasts (27,28).
Secondly, ingenuity interrogation of the illumina data
identiﬁed AMPK signaling as a signiﬁcantly regulated
pathway. Therefore, we undertook western analysis of
the basal and phosphorylated AMPK species (Figure
6B). We detected no change in total AMPK protein
levels (Figure 6B and C). However, phosphorylated
T172 AMPK levels were signiﬁcantly elevated in skeletal
muscle from Tg-RORa1DE mice (Figure 6B and C).
The increased levels of phospho-AMPK are entirely con-
sistent with reduced Akt2 activity.
Nucleic Acids Research, 2010,Vol.38, No. 13 4305We further investigated the levels of the basal and
phosphorylated AMPK species AMPK in homozygous
staggerer (sg/sg) mice that lack RORa in all tissues (in
contrast, to the muscle-speciﬁc overexpression of the
dominant negative). We detected a slight but signiﬁcant
 1.5-fold increase in total AMPK protein levels (Figure
6D and E) in sg/sg mice relative to wt littermates.
However, the levels of phosphorylated T172 AMPK
levels did not change in the skeletal muscle tissue from
the sg/sg mice relative to wt littermates (Figure 6D and
E). In summary, transgenic and muscle-speciﬁc
overexpression of RORa1DE leads to elevated levels
of phospho-AMPK.
Elevated phospho-AMPK in Tg-RORa1"DE mice
leads to increased phosphoACC Levels, and increased
PGC-1a and CPT-1b mRNA expression
The literature reports that the positive eﬀect of activated
AMPK on fatty acid oxidation is mediated by phosphor-
ylation of Acetyl CoA carboxylase ACC (and decreased
production of malonyl CoA) (see Figure 7A). Moreover,
   Saline
 
   Insulin
p-AKT  
AKT      
Gapdh    
p-AKT  
AKT
Gapdh    
Wild Type
Saline Insulin
200
50
100
150
0
*
N.S.
Saline +
Insulin
D
e
o
x
y
g
l
u
c
o
s
e
 
U
p
t
a
k
e
p
m
o
l
/
m
g
*
m
i
n
Saline
0.8
0.6
0.4
0.2
1.0
0.0
***
D
e
n
s
i
t
y
 
R
e
l
a
t
i
v
e
 
t
o
 
G
A
P
D
H
AKT
Wild Type
Wild Type
0.8
0.6
0.4
0.2
1.0
0.0
D
e
n
s
i
t
y
 
R
e
l
a
t
i
v
e
 
t
o
 
G
A
P
D
H
pAKT
AKT pAKT
Insulin Saline Insulin
Saline Insulin Saline Insulin
Tg/RORα1ΔDE Tg/RORα1ΔDE
Tg/RORα1ΔDE
 -+
+
 -
 - +  -
A
C
E
B
D
Figure 4. (A) and (B) Western blot and densitometry analysis of pAkt, total Akt and Gapdh in skeletal muscle of saline and insulin treated wild-type
(wt) mice, respectively. (C) and (D) Western blot and densitometry analysis of pAkt, total Akt and Gapdh in skeletal muscle of saline and
insulin-treated heterozygous transgenic-RORa1DE mice, respectively. Brieﬂy, fasted mice were IP injected with either saline or insulin (0.5U/
kg). Mice treated with saline (n=4wt and 4 tg) or insulin (n=3wt and 3 tg) was sacriﬁced after 10min and skeletal muscle (quadricep) was excised
and snap frozen. Densitometry expressed as the mean +/  SEM, ***P<0.001 (E) Ex-vivo insulin-stimulated glucose uptake in type II glycolytic
muscle of wt and transgenic-RORa1DE mice (n=7–8). Insulin-stimulated glucose uptake was performed from skeletal muscle (extensor digitorum
longus, EDL) dissected from anesthetized mice and incubated in essential buﬀer (Krebs–Henseleit, pH 7.4) and the assay was performed as described
previously (18,19). *P<0.05, NS, not signiﬁcant.
4306 Nucleic Acids Research, 2010,Vol.38, No. 13AMPK activators increase the expression of PGC-1a and
PPARa target genes, for example CPT-1 in skeletal muscle
(29,30). Consequently, we were particularly interested to
assess whether increased expression of activated AMPK
resulted in the induction of phosphoACC (Ser79) and two
critical genes associated with fatty acid oxidation in the
skeletal muscle of the Tg-RORa1DE mice.
We undertook analysis of the basal and phosphorylated
ACC species (Figure 7B). We detected a signiﬁcant change
in total ACC protein levels (Figure 7B). More important-
ly, phosphorylated ACC levels (detected by western blot)
were signiﬁcantly elevated in skeletal muscle from
Tg-RORa1DE mice (Figure 7B and C). qPCR analysis
revealed the signiﬁcant (diﬀerential) expression of the
mRNAs encoding PGC-1a (Figure 7D) and CPT-1b
(Figure 7E) in the skeletal muscle of male
Tg-RORa1DE mice relative to wild-type littermates.
The elevated levels of pACC and PGC-1a and CPT-1
mRNA expression in the Tg mice are consistent with
increased levels of pAMPK and pACC.
Expression of the truncated orphan nuclear receptor,
RORa1 had minimal eﬀects on important skeletal
muscle markers of ﬁber type and muscle mass
We utilized qPCR-TLDA analysis to assess whether the
expression of the truncated receptor aﬀect markers of con-
tractile function, ﬁber type and muscle mass (see Table 3,
Supplementary Figure S9). Speciﬁcally, in this context,
TLDA analysis revealed signiﬁcant diﬀerential expression
of the mRNAs encoding histone deacetylase 5 (HDAC5),
transforming growth factor beta receptor 1 (Tgfbr1) and
several other genes (including Mef2a/d, Tnni2 and
Acvr2A) in the skeletal muscle of male Tg-RORa1DE
mice relative to wild-type littermates (see Table 3,
Supplementary Figure S9) when normalized against 18S
rRNA. However, following the application of conserva-
tive data ﬁltering using the FDR–Benjamini–Hochberg
algorithm, only HDAC5 ( 1.25-fold) and Tgfbr1
(2.5-fold) survived as signiﬁcant (but weak) decreases in
expression (Table 3, and Supplementary Figure S9). This
suggested that the changes in glucose tolerance, insulin
signaling and lipogenesis were not indirect eﬀects of
changes in muscle mass and/or contractile function.
DISCUSSION
The biochemical and molecular characterization of RORs
in cell culture and animal models has revealed that RORs
play a critical role in the modulation of lipid homeostasis
in a tissue-speciﬁc manner (1–5,31,32). Our previous
studies reported that homozygous (male and female) stag-
gerer mice (with decreased and dysfunctional expression
of RORa in all organs) display reduced adiposity and are
resistant to high-fat diet-induced obesity. The lean pheno-
type of staggerer mice was associated with signiﬁcantly
increased expression of genes involved in fatty acid oxida-
tion (including PGC-1, lipin1, etc.), and signiﬁcantly
reduced expression of SREBP-1c (and several lipogenic
genes) in all major metabolic tissues.
Surprisingly, studies investigating the role of RORa in
the regulation of glucose homeostasis have not been
reported. In this context, we were particularly interested
in exploring the role of RORa1 in skeletal muscle, a major
mass peripheral tissue that accounts for the majority of
glucose disposal and lipid catabolism. We probed the role
of RORa signaling in this major mass peripheral tissue, by
the skeletal muscle-speciﬁc overexpression of truncated
RORa1DE (lacking the ligand-binding domain) to in-
vestigate the contribution of this peripheral tissue to the
RORa phenotype. This construct has been described to
operate in a dominant negative manner in several
reports (21,22). This strategy also allows the probing of
RORa-dependent gene expression in the absence of an
identiﬁed native and/or synthetic ligand.
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4308 Nucleic Acids Research, 2010,Vol.38, No. 13The human skeletal a-actin promoter was utilized to
construct the muscle-speciﬁc vector. This promoter
has been demonstrated to function in a cell/tissue-
speciﬁc manner (10,11). As expected the transgene,
RORa1DE, was eﬃciently and speciﬁcally expressed in
skeletal muscle of transgenic mice relative to other organ/
tissues. Second, our RORa1DE expression vector
retains the native RORa1 amino-terminal AF-1 domain
(i.e. AB region) and the native zinc ﬁnger region; these
properties ensure that the NR targets the native RORa1
response elements in the skeletal muscle of transgenic
mice. Giguere et al. (26) demonstrated that each ROR
isoform displays isoform-speciﬁc DNA binding, and the
amino-terminal domain and the zinc ﬁnger region work in
parallel to confer sequence-speciﬁc DNA recognition and
binding.
Expression proﬁling, coupled to analysis on the ingenu-
ity platform identiﬁed a RORa1-regulated subset of genes
that were involved in or associated with lipid metabolism,
small molecule transport and biochemistry, cardiovascular
and metabolic disease, carbohydrate metabolism, endo-
crine system disorders etc. This is in concordance with
investigations in RORa-deﬁcient mouse models and
in vitro promoter/cell culture investigations that have
demonstrated the involvement of RORa in a number of
physiological process including atherosclerosis, lipid
homeostasis, fat deposition, obesity, inﬂammation,
immunity, etc (6). In the framework of this investigation,
the primary signaling pathways regulated in skeletal
muscle were glutathione metabolism (that tightly
controls ROS levels and modulates insulin sensitivity),
type 2 diabetic signallng and fatty acid biosynthesis.
Notably, the LXR signaling (and RXR dependent)
pathway was identiﬁed in the analysis, which controls
lipogenesis and cholesterol homeostasis.
In concordance with the array analysis, qPCR analysis
on the TLDA platform revealed signiﬁcantly attenuated
expression of the mRNAs (encoding the hierarchical regu-
lators of lipogenesis), LXRa and SREBP-1c and several
other downstream target genes involved in fatty acid bio-
synthesis in skeletal muscle. For example, we observed
decreased expression of the downstream target genes,
SCD1 and FAS. Moreover, in the context of lipogenesis,
we observed the suppression of Ascl4, Dgat2, Tip47,
HIF-1 and Cd36. Acsl4, the long chain acyl CoA
synthetase, plays an important role in lipid metabolism
by routing fatty acids to several diﬀerent metabolic
pools. Decreased Acsl4 expression is associated with
decreased triglycerides and fatty acids partitioning to di-
and tri-acyl glycerol (33,34) and consistent with reduced
Dgat2 (that catalyzes the ﬁnal step in triglyceride produc-
tion) and Tip47 (a perilipin family member that
co-ordinates the storage of triacylglycerol (35).
Furthermore, it has been reported that decreased Dgat2
expression is associated with reduced expression of
SREBP-1c and SCD-1 and increased CPT-1 expression
(see below), in concordance with our observations (36).
Finally, suppression of HIF-1alpha is associated with
reduced fatty acid uptake and biosynthesis, and in con-
cordance with the suppression of the genetic program
controlling lipogenesis and the decrease in the fatty acid
translocase, CD36 (37).
In the context of the decrease in LXR and other NR
signaling pathways, we completed TLDA analysis of the
entire NR supergene family. This analysis identiﬁed de-
creases in the expression of the mRNAs encoding GR,
PPARd, TR2 and RORg. These nuclear receptors have
been implicated in the regulation of lipid homeostasis.
We did not observe decreases in THR(a/b), FXR,
VDR, etc. that were identiﬁed by ingenuity. We suggest
that the detection of these pathways by ingenuity reﬂects
secondary consequences of RORa-mediated dysregulation
and the aberrant expression of NRs identiﬁed above.
As discussed, ingenuity analysis of the array data
identiﬁed carbohydrate metabolism as a signiﬁcantly
regulated function. We observed the male
tg-RORa1DE mice display signiﬁcantly increased
fasting plasma glucose levels, impaired glucose tolerance
and attenuated insulin-stimulated glucose uptake relative
to wild-type littermates. Our qPCR TLDA proﬁling
identiﬁed the signiﬁcantly decreased expression of the
mRNA encoding Akt2/PKB in skeletal muscle, after
Bayes assignment of signiﬁcance and stringent FDR ﬁlter-
ing. Furthermore, the total amount of Akt and
phospho-Akt protein was signiﬁcantly reduced. In this
context, several studies have demonstrated that, Akt2
plays a critical role in insulin-mediated glucose disposal
in skeletal muscle. For example, Cho et al. (38)
demonstrated that disruption of the Akt2 gene expression
in mice was associated with insulin resistance and type2
diabetes-like syndrome. Subsequently, Garofalo et al. (39)
showed mice lacking Akt2/PKB gene displayed a diabetic
phenotype and age-dependant lipodystrophy.
Interestingly, the mild hyperglycemia (in the fasted
state), glucose intolerance and impaired glucose uptake
occur without any signiﬁcant change in whole body
insulin sensitivity (i.e. the insulin tolerance test) and/or
change in GLUT1 and four expression. First, this does
not appear to involve an insulin secretion defect as the
transgene is not expressed in the pancreas and the mice
develop hyperinsulinemia after a high-fat challenge (data
not shown). It should be noted that muscle-speciﬁc
deletion of an essential component (rictor) of the mTOR
complex 2 leads to the attenuation of insulin-induced
phosphorylation of Akt2 at Ser473. Moreover, these
mice displayed glucose intolerance, however, insulin sen-
sitivity remained unchanged (40). Similarly, our
Tg-RORa1DE mice displayed an attenuated insulin-
mediated Ser473 phosphorylation of Akt and glucose
uptake. In this context, Gonzalez and McGraw (41)
demonstrated that ‘insulin signalling diverges into
Akt-dependent and independent signals’. James and col-
leagues (42) recently stated that several studies underscore
the pivotal role of Akt2 in GLUT4 function; however,
many gaps remain in understanding the signaling
cascades involved. For example, similar inconsistencies
(between impaired glucose uptake and/or normal glucose
tolerance and insulin sensitivity) have been described in
other animal models that have perturbed expression
and/or knockout in critical genes that regulate glucose
homeostasis.
Nucleic Acids Research, 2010,Vol.38, No. 13 4309ChIP analysis revealed RORal was directly involved in
the regulation of Akt2. We identiﬁed several potential
RORa1 response elements in the mouse Akt2 promoter
between  2900 and  2600nt upstream of the transcrip-
tion start site. These sites were accommodated by the
motif R=A
Y=A
T=A
T=R
T=A
Y=TRGGTCA described by Giguere
et al. (26), as an optimal RORa1-binding site. ChIP
identiﬁed functional RORa1 recruitment to three sites
(in close proximity) within this region. Further character-
ization of the Akt2 promoter is required to elucidate the
mechanism mediating regulation by RORa1.
Ingenuity identiﬁed AMPK signaling as a regulated
pathway in the Tg mice overexpressing the dominant
negative RORa1. It has been well established that
AMPK is master regulator of energy homeostasis
through the suppression of ATP-consuming lipogenic
pathways and by the enhancement of ATP producing
catabolic pathways, including fatty acid oxidation in
skeletal muscle tissue (43,44 and references therein).
Moreover, Akt2/PKB is a potent modulator of AMPK
activity. For example, Hahn-Windgassen et al. (28)
showed that Akt/PKB regulates intracellular ATP levels
through regulating AMPK activity. Furthermore,
Planavila et al. (45) showed that mice treated with
troglitazone (PPARg agonist) in skeletal muscle were
associated with increased Akt2/PKB and decreased
AMPK activity. Moreover, recent investigations on
Akt2/PKB and AMPK pathways in heart tissue showed
that Akt2/PKB is a negative regulator of AMPK activity
(27). Finally, the association between increased AMPK
activity and the reduction of lipogenic gene expression
and genes regulating fatty acid oxidation is well docu-
mented (46–49). Furthermore, the inhibitory eﬀect of
potent AMPK activators such as aminoimidazole
carboxamide ribonucleotide (AICAR) or Metformin on
lipogenesis in skeletal muscle has been described in both
human and rodents (29,30). Consequently, in the context
of our studies, we were particularly interested in
examining the cross-talk between lipid homeostasis (lipo-
genesis and fatty acid oxidation), Akt2 signaling (and
glucose tolerance) and AMPK signaling in a background
of aberrant RORa1 (NR) signaling.
Interestingly, the hyperglycemia and signiﬁcantly
decreased Akt2 (mRNA and protein) and phosphoAKT
levels in the Tg-RORa1DE mice are associated with
increased phosphoAMPK levels, in concordance with
the studies discussed above. This is consistent
with studies demonstrating type 2 diabetic patients also
display normal AMPK signaling (50,51). Paradoxically,
some studies report that increased AMPK activity
mediates (only exercise induced) glucose transport.
However, AMPK null mice exhibit typical exercise
stimulated glucose uptake in skeletal muscle and AICAR
does not induce glucose transport in muscle (52).
Interestingly, we did not observe increases in pAMPK in
the skeletal muscle of staggerer (sg/sg) mice that lack
RORa expression in all tissues (although we observed
mild elevation in the levels of basal/total AMPK).
Diﬀerential AMPK activity in these lines is not completely
unexpected for several reasons. Firstly, we are comparing
a line of mice overexpressing dominant negative RORa1
(in skeletal muscle), against a line of mice lacking RORa1
expression. Second, in mice lacking NR expression, genes
(and/or phenotypes) maybe silenced or derepressed de-
pending on cofactor requirements, expression and/or
promoter characteristics (53).
The increased AMPK activity in the Tg-RORa1DE
mice did not only correlate with decreased Akt activity,
but was also consistent with (i) attenuated mRNA expres-
sion of LXRa and SREBP-1c, and several other genes
involved in fatty acid biosynthesis in skeletal muscle
(44,54,55) and (ii) induction of the genes/pathways
increasing fatty acid oxidation (56). For example, SCD1
deﬁciency has been reported to be associated with
increased AMPK activity, fatty acid oxidation and
reduced ceramide synthesis (41,42,57). In addition, in
this interconnected regulatory milieu, we observed
increased expression of two critical regulators of fatty
acid oxidation, PGC-1a and CPT1b, concomitant with
elevated levels of phospho-Ser79 ACC in the
Tg-RORa1DE mice, relative to the wt littermate mice.
This is also consistent with the observations (47–49,56 and
references therein) that activated AMPK and AMPK
agonists regulate PGC-1 and pACC expression.
Finally, overexpression of truncated RORa in skeletal
muscle resulted in very minor changes in the expression of
genes regulating muscle mass, proliferation and diﬀerenti-
ation. Interestingly, the analysis did identify HDAC5 as a
diﬀerentially expressed gene. A recent study has
demonstrated the link between AMPK, energy balance
and transcriptional regulation of GLUT4 expression
mediated by HDAC5. That study indicated that increased
AMPK activity induced HDAC phosphorylation that
reduces HDAC5 association with the GLUT4 promoter.
Interestingly, in our mouse model, although insulin
mediated phosphorylation of Akt2, and glucose uptake
was perturbed; the association between increased AMPK
activity and HDAC5 was maintained.
In conclusion our investigation reveals that the or-
phan nuclear receptor RORa operates at the nexus of
pathways controlling the association between lipid
homeostasis (lipogenesis, and fatty acid oxidation), Akt2
signaling (glucose tolerance and uptake) and AMPK
signaling.
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